{"id":473412,"date":"2023-09-28T00:40:43","date_gmt":"2023-09-28T07:40:43","guid":{"rendered":"https:\/\/nai500.com\/blog\/2023\/09\/%e7%b3%96%e5%b0%bf%e7%97%85%e5%92%8c%e5%87%8f%e8%82%a5%e8%8d%af%e8%b5%9b%e9%81%93%e6%8c%81%e7%bb%ad%e7%81%ab%e7%83%ad-%e8%82%a1%e7%a5%a8\/"},"modified":"2023-09-28T00:41:02","modified_gmt":"2023-09-28T07:41:02","slug":"%e7%b3%96%e5%b0%bf%e7%97%85%e5%92%8c%e6%b8%9b%e8%82%a5%e8%97%a5-%e8%b3%bd%e9%81%93-%e6%8c%81%e7%ba%8c%e7%81%ab%e7%86%b1-%e8%82%a1%e7%a5%a8","status":"publish","type":"post","link":"https:\/\/nai500.com\/zh-hant\/blog\/2023\/09\/%e7%b3%96%e5%b0%bf%e7%97%85%e5%92%8c%e6%b8%9b%e8%82%a5%e8%97%a5-%e8%b3%bd%e9%81%93-%e6%8c%81%e7%ba%8c%e7%81%ab%e7%86%b1-%e8%82%a1%e7%a5%a8\/","title":{"rendered":"\u7cd6\u5c3f\u75c5\u548c\u6e1b\u80a5\u85e5\u8cfd\u9053\u6301\u7e8c\u706b\u71b1\uff0c\u9019\u4e9b\u80a1\u7968\u6210\u4e86\u83ef\u723e\u8857\u7684\u5bf5\u5152"},"content":{"rendered":"<p>2023\u5e74\uff0c\u85e5\u7269\u6e1b\u91cd\u5e02\u5834\u9032\u5165\u5168\u9762\u64f4\u5f35\u6a21\u5f0f\u3002Fortune Business Insights\u7684\u5831\u544a\u986f\u793a\uff0c\u5168\u7403\u6e1b\u80a5\u85e5\u5e02\u5834\u9810\u8a08\u5c07\u5f9e2023\u5e74\u768445\u5104\u7f8e\u5143\u589e\u81f32030\u5e74\u7684229\u5104\u7f8e\u5143\uff0c\u5e74\u8907\u5408\u589e\u9577\u7387\uff08CAGR\uff0926.1%\u3002<\/p>\n<p>\u9019\u500b\u5e02\u5834\u6b63\u84ec\u52c3\u767c\u5c55\uff0c\u539f\u56e0\u662f\u7f8e\u570b\u7cd6\u5c3f\u75c5\u548c\u80a5\u80d6\u75c7\u6210\u4eba\u6578\u91cf\u5275\u6b77\u53f2\u4e4b\u6700\u3002\u7f8e\u570b\u75be\u75c5\u63a7\u5236\u8207\u9810\u9632\u4e2d\u5fc3\uff08CDC\uff092021\u5e74\u7684\u4e00\u9805\u9810\u6e2c\u986f\u793a\uff0c\u7f8e\u570b\u6bcf\u5e74\u8ddf\u80a5\u80d6\u75c7\u76f8\u95dc\u7684\u764c\u75c7\u75c5\u4f8b\u6578\u91cf\u8d85\u904e65\u842c\u3002\u8207\u6b64\u540c\u6642\uff0c\u4e16\u754c\u885b\u751f\u7d44\u7e54\uff08WHO\uff09\u5831\u544a\u5168\u7403\u80a5\u80d6\u4eba\u53e3\u6578\u91cf\u8d85\u904e10\u5104\u3002<\/p>\n<p>\u53e6\u64da\u6700\u65b0\u7684\u300aCDC\u5168\u570b\u7cd6\u5c3f\u75c5\u7d71\u8a08\u5831\u544a\u300b\uff0c\u7f8e\u570b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4eba\u6578\u8d85\u904e3700\u842c\uff0c\u4eba\u53e3\u5360\u6bd411.3%\u3002\u66f4\u8b93\u4eba\u5482\u820c\u7684\u662f\uff0c9600\u842c\u5e74\u6eff18\u6b72\u7684\u6210\u4eba\u8655\u65bc\u7cd6\u5c3f\u75c5\u524d\u671f\uff0c\u5360\u7f8e\u570b\u6210\u4eba\u6578\u91cf\u768438%\u3002<\/p>\n<p>\u5982\u6b64\u4e00\u584a\u201c\u80a5\u8089\u201d\uff0c\u5404\u5927\u85e5\u4f01\u81ea\u7136\u722d\u76f8\u7814\u767c\u548c\u4e0a\u5e02\u65b0\u7684\u6e1b\u80a5\u85e5\u7269\uff0c\u5e0c\u671b\u5f9e\u4e2d\u5206\u5f97\u4e00\u676f\u7fb9\u3002\u6709\u7684\u516c\u53f8\u7684\u4e8c\u578b\u7cd6\u5c3f\u75c5\u85e5\u7269\u5df2\u7d93\u7372\u6279\uff0c\u4f46\u80a5\u80d6\u75c7\u9069\u61c9\u75c7\u5f85\u6279\u3002<\/p>\n<p>\u6469\u6839\u58eb\u4e39\u5229\u7684\u6b50\u6d32\u751f\u7269\u88fd\u85e5\u5206\u6790\u5e2bMark Purcell\u8868\u793a\uff0c\u5f97\u76ca\u65bc\u793e\u4ea4\u5a92\u9ad4\u4ee5\u53ca\u91ab\u4fdd\u7684\u53c3\u8207\uff0c\u80a5\u80d6\u75c7\u85e5\u7269\u7684\u9700\u6c42\u5df2\u7d93\u8d85\u51fa\u4e86\u4ed6\u5011\u7684\u9810\u671f\u3002\u6309\u7167\u6469\u6839\u58eb\u4e39\u5229\u7684\u9810\u6e2c\uff0c\u6e1b\u80a5\u8655\u65b9\u85e5\u7684\u5e02\u5834\u898f\u6a21\u52302030\u5e74\u5c07\u589e\u81f3770\u5104\u7f8e\u5143\uff0c\u800c\u8a72\u516c\u53f8\u6b64\u524d\u7684\u9810\u6e2c\u53ea\u6709540\u5104\u7f8e\u5143\u3002<\/p>\n<p>\u5728\u4eba\u5de5\u667a\u80fd\uff08AI\uff09\u80a1\u7968\u7684\u5149\u8292\u4e4b\u4e0b\uff0c\u6e1b\u80a5\u85e5\u88fd\u85e5\u516c\u53f8\u986f\u5f97\u6bd4\u8f03\u4f4e\u8abf\uff0c\u4f46\u5b83\u5011\u4eca\u5e74\u8fc4\u4eca\u7684\u80a1\u50f9\u8868\u73fe\u4e26\u4e0d\u4f4e\u8abf\u3002\u65e2\u7136\u884c\u696d\u57fa\u672c\u9762\u6c92\u6709\u554f\u984c\uff0c\u4e0b\u9762\u90197\u53ea\u6e1b\u80a5\u85e5\u80a1\u7968\u7684\u524d\u666f\u53ef\u671f\u3002<\/p>\n<table width=\"562\">\n<tbody>\n<tr>\n<td>\u80a1\u7968<\/td>\n<td>\u4eca\u5e74\u8fc4\u4eca\u6536\u76ca\u7387<\/td>\n<td>\u96b1\u542b\u80a1\u50f9\u4e0a\u6f32\u7a7a\u9593\uff08\u76f8\u6bd49\u670825\u65e5\uff09<\/td>\n<\/tr>\n<tr>\n<td>Novo Nordisk A\/S (ticker:\u00a0NVO)<\/td>\n<td>38.2%<\/td>\n<td>110.5%<\/td>\n<\/tr>\n<tr>\n<td>Eli Lilly &amp; Co. (LLY)<\/td>\n<td>52.2%<\/td>\n<td>14.6%<\/td>\n<\/tr>\n<tr>\n<td>Amgen Inc. (AMGN)<\/td>\n<td>4.3%<\/td>\n<td>-2.3%<\/td>\n<\/tr>\n<tr>\n<td>Pfizer Inc. (PFE)<\/td>\n<td>-33.6%<\/td>\n<td>33.3%<\/td>\n<\/tr>\n<tr>\n<td>Viking Therapeutics Inc. (VKTX)<\/td>\n<td>24%<\/td>\n<td>174.4%<\/td>\n<\/tr>\n<tr>\n<td>Structure Therapeutics Inc. (GPCR)<\/td>\n<td>27.9%<\/td>\n<td>74.4%<\/td>\n<\/tr>\n<tr>\n<td>Herbalife Ltd. (HLF)<\/td>\n<td>-3.5%<\/td>\n<td>44.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\u7f8e\u80a1\u6e1b\u80a5\u85e5\u80a1\u79681\uff1a\u8afe\u548c\u8afe\u5fb7<\/h2>\n<p>\u4eca\u5e748\u6708\uff0c<a href=\"https:\/\/nai500.com\/zh-hans\/%e8%82%a1%e7%a5%a8%e6%9f%a5%e8%af%a2\/?qm_symbol=NVO\">\u8afe\u548c\u8afe\u5fb7Novo Nordisk\uff08NYSE:NVO\uff09<\/a>\u7684Wegovy\uff08\u7d22\u99ac\u9b6f\u80bd\uff09\u2014\u2014\u5df2\u7d93\u7372\u5f97\u7f8e\u570b\u98df\u54c1\u85e5\u54c1\u76e3\u7ba1\u5c40\uff08FDA\uff09\u6279\u51c6\u6cbb\u7642\u80a5\u80d6\u75c7\u2014\u2014\u8a66\u9a57\u986f\u793a\u9019\u6b3e\u85e5\u7269\u80fd\u5920\u5c07\u80a5\u80d6\u548c\u8d85\u91cd\u60a3\u8005\u7684\u5fc3\u81df\u75c5\u767c\u4f5c\u6216\u4e2d\u98a8\u7684\u98a8\u96aa\u964d\u4f4e20%\uff0c\u96a8\u5f8c\u5927\u578b\u4fdd\u96aa\u516c\u53f8\u4ee5\u53ca\u7f8e\u570b\u7684\u8001\u5e74\u548c\u6b98\u969c\u5065\u5eb7\u4fdd\u96aa\uff08Medicare\uff09\u958b\u59cb\u5c07\u9019\u6b3e\u6e1b\u80a5\u85e5\u7d0d\u5165\u91ab\u4fdd\u85e5\u7269\u7bc4\u570d\u3002\u6b64\u5916\uff0c\u8afe\u548c\u8afe\u5fb7\u7684\u53e6\u4e00\u6b3e\u7cd6\u5c3f\u75c5\u85e5\u7269Ozempic\u4e5f\u5927\u7372\u6210\u529f\u3002<\/p>\n<h2>\u7f8e\u80a1\u6e1b\u80a5\u85e5\u80a1\u79682\uff1a\u79ae\u4f86<\/h2>\n<p>\u672a\u4f8610\u5e74\u751a\u81f3\u5728\u66f4\u9577\u7684\u6642\u671f\u5167\uff0c\u79ae\u4f86Eli Lilly and Co\uff08NYSE:LLY\uff09\u9810\u8a08\u90fd\u5c07\u662f\u6e1b\u80a5\u85e5\u5e02\u5834\u4e0a\u7684\u4e00\u9738\u30022022\u5e745\u6708\uff0c\u7f8e\u570bFDA\u6279\u51c6\u79ae\u4f86\u7684Mounjaro\u6cbb\u7642\u4e8c\u578b\u7cd6\u5c3f\u75c5\uff0c\u4f46\u5206\u6790\u5e2b\u8a8d\u70ba\u9019\u6b3e\u85e5\u5728\u6e1b\u80a5\u5e02\u5834\u4e0a\u7684\u524d\u666f\u4e5f\u975e\u5e38\u53ef\u89c0\u3002Mounjaro\u7684\u5f8c\u671f\u6e1b\u80a5\u8a66\u9a57\u53d6\u5f97\u4e86\u6210\u529f\uff0c\u5f88\u591a\u5206\u6790\u5e2b\u9810\u8a08\u6e1b\u80a5\u9069\u61c9\u75c7\u6709\u53ef\u80fd\u6703\u5728\u4eca\u5e74\u665a\u4e9b\u6642\u5019\u7372\u6279\uff0c\u5e74\u6536\u5165\u9810\u6e2c\u6700\u9ad8\u6253\u5230\u4e86250\u5104\u7f8e\u5143\u3002<\/p>\n<h2>\u7f8e\u80a1\u6e1b\u80a5\u85e5\u80a1\u79683\uff1a\u5b89\u9032<\/h2>\n<p>\u79ae\u4f86\u548c\u8afe\u548c\u8afe\u5fb7\u662f\u6e1b\u80a5\u85e5\u5e02\u5834\u4e0a\u7684\u5169\u5927\u9f8d\u982d\uff0c\u800c\u5f8c\u4f86\u8005\u5b89\u9032Amgen\uff08NASDAQ:AMGN\uff09\u8655\u65bc\u8ffd\u8d95\u614b\u52e2\u4e2d\u3002\u8a72\u516c\u53f8\u7684\u53ef\u6ce8\u5c04\u80a5\u80d6\u75c7\u85e5\u7269AMG133\u9810\u8a082026\u5e74\u4e4b\u524d\u90fd\u4e0d\u6703\u4e0a\u5e02\uff0c\u4f46\u4e00\u671f\u8a66\u9a57\u7d50\u679c\u986f\u793a\u60a3\u8005\u5728\u85e5\u7269\u6cbb\u76423\u500b\u6708\u5f8c\u6e1b\u91cd\u7387\u905414.5%\uff0c\u540c\u6642\u4e8c\u671f\u8a66\u9a57\u7d50\u679c\u9810\u8a08\u5c07\u57282024\u5e74\u51fa\u7210\u3002<\/p>\n<h2>\u7f8e\u80a1\u6e1b\u80a5\u85e5\u80a1\u79684\uff1a\u8f1d\u745e<\/h2>\n<p>\u8f1d\u745e\u88fd\u85e5Pfizer\uff08NYSE:PFE\uff09\u6b63\u5728\u7d93\u6b77\u85e5\u54c1\u7d44\u5408\u6230\u7565\u7684\u8f49\u578b\uff0c\u5176\u4e2d\u5305\u62ec\u767c\u529b\u6e1b\u80a5\u85e5\u9818\u57df\u3002\u516c\u53f8\u76ee\u524d\u6b63\u5728\u9032\u884c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u548c\u6e1b\u80a5\u85e5\u7269danuglipron\u7684\u8a66\u9a57\u4e26\u4e14\u521d\u671f\u7d50\u679c\u7a4d\u6975\uff0c\u6b64\u5916\u9996\u5e2d\u57f7\u884c\u5b98Albert Bourla\u4e5f\u770b\u597d\u8a72\u85e5\u7684\u524d\u666f\uff0c\u7a31\u5b83\u7684\u5e74\u6536\u5165\u6700\u7d42\u53ef\u4ee5\u9054\u5230100\u5104\u7f8e\u5143\u3002<\/p>\n<h2>\u7f8e\u80a1\u6e1b\u80a5\u85e5\u80a1\u79685\uff1aViking Therapeutics<\/h2>\n<p>\u52a0\u5229\u798f\u5c3c\u4e9e\u5dde\u8056\u5730\u4e9e\u54e5\u7684Viking Therapeutics Inc\uff08NASDAQ:VKTX\uff09\u4e5f\u5728\u958b\u767c\u81ea\u5df1\u7684GLP-1\uff08\u80f0\u9ad8\u8840\u7cd6\u7d20\u6a23\u80bd-1\uff09\u80a5\u80d6\u75c7\u7cd6\u5c3f\u75c5\u548c\u6e1b\u80a5\u85e5\u7269\u3002\u516c\u53f8\u9810\u8a08VK2735\u6ce8\u5c04\u7642\u6cd5\u7684\u4e00\u671f\u8a66\u9a57\u7d50\u679c\u5c07\u572810\u6708\u516c\u4f48\uff0c\u53e6\u5916\u53e3\u670d\u85e5\u7684\u7d50\u679c\u9810\u8a08\u5c07\u572812\u6708\u51fa\u7210\u3002<\/p>\n<h2>\u7f8e\u80a1\u6e1b\u80a5\u85e5\u80a1\u79686\uff1aStructure Therapeutics<\/h2>\n<p>Structure Therapeutics Inc.\uff08NASDAQ:GPCR\uff09\u7684\u6e1b\u80a5\u85e5\u5927\u6982\u7387\u57282029\u5e74\u4e4b\u524d\u4e0d\u6703\u4e0a\u5e02\uff0c\u4e0d\u904e\u8a72\u516c\u53f8\u6cbb\u7642\u4e8c\u578b\u7cd6\u5c3f\u75c5\u548c\u80a5\u80d6\u75c7\u7684GSBR-1290\u53e3\u670dGLP-1\u85e5\u7269\u76ee\u524d\u8655\u65bc\u521d\u671f\u8a66\u9a57\u968e\u6bb5\uff0c\u5982\u679c\u8a66\u9a57\u7d50\u679c\u7a4d\u6975\uff0c2b\u671f\u8a66\u9a57\u5c07\u65bc2024\u5e74\u555f\u52d5\u3002GSBR-1290\u76842a\u671f\u7814\u7a76\u7684\u9802\u7dda\u6578\u64da\u9810\u8a08\u5c07\u5728\u5e74\u5e95\u516c\u4f48\u3002<\/p>\n<h2>\u7f8e\u80a1\u6e1b\u80a5\u85e5\u80a1\u79687\uff1a\u5eb7\u5bf6\u840a<\/h2>\n<p>\u5eb7\u5bf6\u840a\u71df\u990aHerbalife Nutrition\uff08NYSE:HLF\uff09\u4e0d\u662f\u88fd\u85e5\u5546\uff0c\u800c\u662f\u4e00\u5bb6\u5e02\u503c13\u5104\u7f8e\u5143\u7684\u4fdd\u5065\u54c1\u516c\u53f8\uff0c\u5176\u4e2d\u6e1b\u91cd\u7ba1\u7406\u662f\u5b83\u76ee\u524d\u6700\u5927\u7684\u4e00\u584a\u696d\u52d9\uff0c\u5360\u5176\u5e74\u6536\u5165\u768457%\u3002\u96a8\u8457\u6d88\u8cbb\u8005\u6e1b\u91cd\u652f\u51fa\u7684\u589e\u9577\uff0c\u5eb7\u5bf6\u840a\u9810\u8a08\u672a\u4f863\u5e74\u548c5\u5e74\u7684\u589e\u901f\u5206\u5225\u70ba14.9%\u548c15.4%\uff0c\u8dd1\u8d0f\u540c\u884c\u696d74%\u548c84%\u7684\u516c\u53f8\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>2023\u5e74\uff0c\u85e5\u7269\u6e1b\u91cd\u5e02\u5834\u9032\u5165\u5168\u9762\u64f4\u5f35\u6a21\u5f0f\u3002Fortune Business Insights\u7684\u5831\u544a\u986f\u793a\uff0c\u5168\u7403\u6e1b [&hellip;]<\/p>\n","protected":false},"author":27,"featured_media":473409,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1522,431],"tags":[577,927,2001,564],"class_list":{"0":"post-473412","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","6":"hentry","7":"category-1522","8":"category-trends-strategies-zh-hant","9":"tag--zh-hant","10":"tag-927","12":"tag-564","13":"sectors-life-science-zh-hant","14":"locations-us-zh-hant","15":"exchange-nasdaq-zh-hant","16":"exchange-nyse-zh-hant"},"acf":[],"_links":{"self":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/473412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/comments?post=473412"}],"version-history":[{"count":0,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/posts\/473412\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media\/473409"}],"wp:attachment":[{"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/media?parent=473412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/categories?post=473412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nai500.com\/zh-hant\/wp-json\/wp\/v2\/tags?post=473412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}